Legitimate online peptide therapy clinics prescribe peptides after a telehealth evaluation and labs, and fill them through licensed compounding pharmacies. As of September 2026, popular peptides like BPC-157 are still in regulatory limbo: an FDA advisory committee voted in July to allow compounding, but the FDA hasn't finalized that change. Among the clinics we review, Hone Health and Marek Health list prescription peptides.
This page covers only prescription-based care through licensed clinicians. It doesn't cover "research chemical" vendors, and it doesn't give dosing information. It's general information, not medical advice.
What peptide therapy is
Peptides are short chains of amino acids. Some are established, FDA-approved medicines (insulin and GLP-1 drugs are peptide-based). The "peptide therapy" offered by wellness and hormone clinics usually refers to compounded peptides such as sermorelin, BPC-157 or TB-500, prepared by a pharmacy for an individual prescription.
The FDA is clear that "compounded drugs are not FDA-approved," which means it does not verify their safety, effectiveness or quality before they're marketed (FDA).
Where the law stands in 2026
2026 has been an unusually busy year for peptide regulation:
- February 27, 2026: HHS Secretary Robert F. Kennedy Jr. announced that about 14 of 19 peptides on the FDA's "Category 2" list (bulk substances with significant safety concerns) would move off it, including BPC-157, TB-500, KPV, MOTS-c and Semax. Others, such as Melanotan II, GHRP-2 and GHRP-6, were expected to stay restricted (Pharmacy Times).
- July 23–24, 2026: The FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides nominated for the 503A bulks list (FDA). It voted 8-6 (one abstention) in favor of BPC-157, KPV and TB-500, and 7-5 for MOTS-c (PharmExec). Across both days, the committee backed six of the seven (Buchanan Ingersoll & Rooney).
- FDA staff disagreed. Agency scientists recommended against inclusion, citing a lack of quality data on safety and effectiveness (ABC News) and noting there's no universally accepted chemical definition for some of these compounds (PharmExec).
What that means now: advisory votes are non-binding. The FDA still has to decide, publish a proposed rule and take public comment before pharmacies have clear legal authority to compound these peptides (Buchanan Ingersoll & Rooney). One legal expert quoted by PharmExec estimated that rulemaking could take eight to twelve months. And even when it's complete, being compoundable is not the same as FDA approval: as Pharmacy Times puts it, reclassification provides no "proven safety, proven efficacy, or standardized dosing."
How prescription peptide therapy works online
A legitimate process looks much like online TRT:
- Evaluation. An intake and telehealth visit with a licensed clinician.
- Labs. Expect baseline blood work before a prescription. Marek Health, for example, runs panels of 50+ biomarkers before a provider builds a protocol (Marek).
- Prescription. Filled by a licensed pharmacy, not bought from a website.
- Follow-up. Ongoing consults and repeat labs.
Your clinician decides whether a peptide is appropriate and how it's used. We don't publish dosing.
Clinics that offer prescription peptides
Hone Health
Hone's medication list for members includes sermorelin (under longevity and wellness) and a PT-141 spray (under sexual health), available with a Plus or Premium membership (Hone). Membership is $135/month plus medication. Read our Hone Health review · Visit Hone Health
Marek Health
Marek Health lists peptide therapies alongside hormone testing, supplement protocols and metabolic care, with a health coach and a licensed provider working from 50+ biomarker labs and quarterly follow-ups (Marek). It charges a $299 one-time intake plus labs, and its program is available in all 50 states, though specific treatments may be state-limited (Marek FAQ). It doesn't name the peptides it prescribes on the pages we checked, so ask. Read our Marek Health review · Visit Marek Health
We'll add more clinics as we verify their peptide offerings, prescribing process and state coverage.
Clinics vs "research peptide" vendors
Search results for peptides are full of websites selling vials labeled "for research use only." Those aren't prescription therapy: there's no clinician evaluation, no pharmacy oversight and no guarantee of what's in the vial. FDA scientists' concern that some peptides lack an accepted chemical definition (PharmExec) is exactly why sourcing matters. Stick to clinics where a licensed clinician prescribes and a licensed pharmacy dispenses.
What peptide therapy costs
Pricing varies by peptide, pharmacy and clinic, and neither Hone nor Marek publishes a peptide price list on the pages we checked. Hone's sermorelin requires a Plus ($135/month) or Premium ($155/month) membership plus the medication cost; Marek charges a $299 intake plus labs, with medication billed separately. Insurance generally doesn't apply: neither clinic accepts insurance, though Hone accepts HSA/FSA cards and Marek provides invoices for HSA/FSA reimbursement. Ask for a full written quote, including labs and follow-ups.
How to vet an online peptide clinic
Ask:
- Who prescribes? Get the clinician's name and license type.
- Which pharmacy fills it, and is it licensed in your state?
- Is the peptide currently compoundable? Given the 2026 changes, a careful clinic can explain the current status of what it prescribes.
- What labs are required, before and during treatment?
- What are the known risks and how will they be monitored?
- Does the clinic make treatment claims? Be wary of promises to cure, heal or reverse aging. Human evidence for many popular peptides is limited; ABC News notes most studies of BPC-157 have been in rodents, not people (ABC News).
Risks
Because compounded peptides aren't FDA-approved and many have little human trial data, their safety and effectiveness aren't established. Discuss risks with a licensed clinician, and tell them about every medication you take, including testosterone. For TRT-specific risks, see TRT side effects and risks.